
	Where results make sense

Topic: Genentech

Related Topics

Growth hormone treatment

Growth hormone deficiency

Alphapharm

Biogen Idec

Growth hormone

Lundbeck

Lists of companies

Amgen

Green biotechnology

Gilead Sciences

Alza

Almirall Prodesfarma

Herbert Boyer

Golden rice

Abbott Laboratories

	Genentech: Home
		On February 22, 2008, the FDA granted accelerated approval for Avastin in combination with paclitaxel chemotherapy for the first-line treatment of advanced HER2-negative breast cancer.
		Genentech is committed to making sure price is not a barrier to access for patients.
		Genentech's postdoctoral program offers the chance to do cutting-edge research in an inspiring environment.
	www.gene.com (142 words)

	Genentech - Wikipedia, the free encyclopedia
		Genentech, Inc. (NYSE: DNA), a composite of Genetic Engineering Technology, Inc., is a leading biotechnology corporation, which was founded in 1976 by Robert A. Swanson, a venture capitalist, and biochemist Dr. Herbert W. Boyer.
		Genentech was named one of the 100 Best Companies for Working Mothers in 2004 by Working Mothers magazine.
		Genentech's corporate headquarters is at South San Francisco, CA, with additional manufacturing facilities in Vacaville, California and Porrino, Spain.
	en.wikipedia.org /wiki/Genentech (585 words)

	UCSF - Mission Bay - Image Database
		Genentech Hall may be a new home for science, but its tricks of light and shadow are also giving new inspiration to photographers.
		Genentech Hall (24A/B), a five occupied-story, 434,000-gross-square-foot biomedical research facility, broke ground in October 1999 and was completed in October 2002.
		One of the 900 occupants of Genentech Hall moves across the striking vertical and horizontal patterns that typify the building.
	pub.ucsf.edu /missionbay/imagedb/index.php?searchword=genentech (1308 words)

	Genentech raises EPS forecast, approvals target - Boston.com
		Genentech employees form a strand of DNA in San Francisco in an undated file photo.
		Genentech said it was looking at its new lung cancer drug Tarceva in pancreatic and breast cancers.
		While Genentech's shares were down about 10 percent this year prior to Friday' meeting, that follows a 70-percent run-up in the share price in 2005 as the stock rode a wave of positive results from clinical trials.
	www.boston.com /business/articles/2006/03/17/genentech_raises_eps_forecast_approvals_target (728 words)

	Former worker sues Genentech over drug marketing - Boston.com
		Genentech, of South San Francisco, Calif., was served with a copy of the suit earlier this month, a Genentech executive disclosed Tuesday after the company reported fourth-quarter earnings.
		Genentech is cooperating with that investigation, which it said was both civil and criminal in nature.
		Biogen and Genentech have applied for FDA approval to market Rituxan as such a treatment, and a decision is expected by late February.
	www.boston.com /news/local/massachusetts/articles/2006/01/11/former_worker_sues_genentech_over_drug_marketing (583 words)

	Novo Nordisk v. Genentech, Inc.
		Novo sued Genentech in district court, seeking a declaratory judgment that the '980 patent is invalid and not infringed by Novo.
		Furthermore, Genentech distinguished the prior art by arguing that the patentable invention "produce[d] [the] desired protein unaccompanied by extraneous conjugated protein, thus for the first time achieving success in producing [the] desired protein in a direct manner." Similar assertions were made throughout the patent's lengthy prosecution.
		Genentech consistently argued during prosecution that the patentable invention was a method of directly expressing human growth hormone; it never argued that the invention included cleavable fusion expression.
	www.ll.georgetown.edu /Federal/judicial/fed/opinions/95opinions/95-1424.html (3484 words)

	Genentech Surges on Test Data
		Genentech (DNA:NYSE - commentary - research) shares surged Friday on news that the company and its Swiss partner may seek U.S. approval of their cancer drug Avastin as a treatment for breast cancer.
		Genentech and Roche said that a study of a combination therapy using Avastin plus the chemotherapy drug paclitaxel showed improved progression-free survival of metastatic breast cancer compared with chemotherapy alone.
		Genentech is also evaluating the use of Avastin for adjuvant and metastatic colorectal, kidney, breast, non-small cell lung, pancreatic, ovarian and prostate cancers.
	www.thestreet.com /_googlen/stocks/biotech/10217801.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA (350 words)

	Genentech no stranger to San Diego North County Times - North San Diego and Southwest Riverside County News - ... (Site not responding. Last check: )
		Genentech Inc. is a newcomer to San Diego County with its $408 million purchase of Biogen Idec's manufacturing plant in Oceanside.
		Genentech's biggest problem was the lack of a "blockbuster" drug, the kind a large pharmaceutical company would covet.
		Genentech officials said there is enough space at the plant's 60-acre site to double its 90,000-liter (95,000-quart) capacity, but there are no plans at this point to do so.
	www.nctimes.com /articles/2005/06/26/business/news/10_35_076_25_05.txt (1823 words)

	WebWire® \| Genentech Provides Updates At Annual Investment Meeting
		Genentech will be offering an archived webcast of the investment community meeting on its website at http://www.gene.com.
		Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs.
		Genentech disclaims, and does not undertake, any obligation to update or revise any forward-looking statements in this press release.
	www.webwire.com /ViewPressRel.asp?aId=11241 (638 words)

	ABC 7 News - Genentech's 4Q Earnings Match Expectations (Site not responding. Last check: )
		Arthur Levinson, Genentech's chief executive, painted a rosy outlook for analysts during a Tuesday conference call, predicting the company will be able to balance Wall Street's desire for short-term financial growth while continuing to develop new drugs that often require years of expensive testing.
		Genentech also excluded stock option expenses of 15 cents to 17 cents per share from its 2006 forecast, which envisions an earnings increase of 35 percent to 45 percent.
		Genentech's management is hoping to win regulatory approval to allow Avastin to treat lung and breast cancers, a breakthrough that would provide a significant sales stimulus.
	www.wjla.com /news/stories/0106/292945.html (798 words)

	Genentech in Competition With Itself on Eye Drug - New York Times
		Lucentis, a drug being developed by Genentech to treat an eye disease that causes blindness in the elderly, is facing competition from a drug that some doctors say they think is as effective, but less than one-tenth the price.
		The other Genentech drug is the blockbuster Avastin, which is approved for treatment of colorectal cancer.
		Shares of Genentech fell $3.28, or 4 percent, to $82.55 yesterday after Eric Schmidt, an analyst at SG Cowen, reduced his estimate for peak annual sales of Lucentis to $600 million, from $1.1 billion, citing potential competition from Avastin.
	www.nytimes.com /2005/09/27/business/27place.html?ex=1285473600&en=738ed22a398e8d5c&ei=5088&partner=rssnyt&emc=rss (982 words)

	Genentech Jobs at San Francisco Chronicle Jobs (Site not responding. Last check: )
		Genentech, the founder of the biotechnology industry, is a company with a quarter-century track record of delivering on the promise of biotechnology.
		Today, Genentech is among the world's leading biotech companies, with multiple protein-based products on the market for serious or life-threatening medical conditions and over 30 projects in the pipeline.
		With its strength in all areas of the drug development process — from research and development to manufacturing and commercialization — Genentech continues to transform the possibilities of biotechnology into improved realities for patients.
	295.careersite.com /candidate/processcandviewcompanyprofile?custId=9F382-0350 (85 words)

Try your search on: Qwika (all wikis)